Trials Sponsors Conditions Drugs Pricing

You may not qualify if:

Subjects presenting with any of the following will not be included in the study:
Evidence or history of clinically significant hepatic, renal, cardiovascular, endocrine, hematologic, gastrointestinal, pulmonary, neurologic, oncologic, psychiatric, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). This also includes subjects with previous history of epilepsy or seizures, clinically significant abnormal electroencephalogram (EEG), febrile convulsion, head injury with significant sequelae, psychiatric illness, attempted suicide or suicidal ideation.
Any condition possibly affecting drug absorption (eg, gastrectomy)
A positive urine drug screen (confirmed by repeat) Protocol 4006 Version 1.0; 20 April 2018 Confidential and Proprietary
History of regular alcohol consumption exceeding 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the dose of study medication.
Screening supine blood pressure ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of rest. If blood pressure (BP) is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.
lead ECG demonstrating QTc \>450 msec or a QRS interval \>120 msec at screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRS values should be used to determine the subject's eligibility.
Males of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
Use of prescription drugs within 7 days or 5 half-lives (whichever is longer) prior to the dose of study medication. As an exception, acetaminophen/paracetamol may be used "as needed" (prn) and only at doses of ≤1 g/day.
Blood donation or loss (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
History of sensitivity to heparin or heparin-induced thrombocytopenia.
Unwilling or unable to comply with the Life Style Guidelines described in this protocol.
Any severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
A lifetime history of seizure disorder of any etiology, inclusive of childhood seizures.
+13 more criteria

D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

PF-06412562

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

PF-06412562

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations